A phase 2 trial found that the apoE mimetic peptide CN-105 was safe and feasible in older adults after surgery, supporting the need for a phase 3 trial to assess effects on postoperative delirium.

This randomized clinical trial investigates the safety and feasibility of the apolipoprotein E mimetic peptide CN-105 vs placebo for reducing postoperative delirium in older patients.